Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients With HER2+ Metastatic Breast Cancer: HERTAX Trial
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2011.03.003
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2011
Authors
Publisher
Elsevier BV